Connor Clark & Lunn Investment Management Ltd. Raises Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 665.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 74,625 shares of the company’s stock after purchasing an additional 64,872 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.22% of TransMedics Group worth $11,716,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of TransMedics Group in the third quarter worth approximately $1,059,000. Pathstone Holdings LLC boosted its holdings in shares of TransMedics Group by 4.9% in the 3rd quarter. Pathstone Holdings LLC now owns 26,381 shares of the company’s stock valued at $4,142,000 after buying an additional 1,231 shares in the last quarter. Thrivent Financial for Lutherans purchased a new position in TransMedics Group in the third quarter worth $4,113,000. Mutual of America Capital Management LLC purchased a new stake in TransMedics Group in the third quarter valued at about $784,000. Finally, Vaughan Nelson Investment Management L.P. raised its position in shares of TransMedics Group by 24.3% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after purchasing an additional 64,360 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Insider Transactions at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This represents a 12.27 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Nicholas Corcoran sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the sale, the insider now directly owns 21,105 shares of the company’s stock, valued at $3,714,902.10. This represents a 32.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 36,958 shares of company stock valued at $5,230,528 over the last quarter. Company insiders own 7.00% of the company’s stock.

TransMedics Group Stock Up 2.8 %

NASDAQ:TMDX opened at $79.34 on Friday. The firm has a market capitalization of $2.66 billion, a PE ratio of 82.13 and a beta of 2.08. TransMedics Group, Inc. has a 52 week low of $67.77 and a 52 week high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The stock has a 50 day moving average of $122.08 and a 200-day moving average of $138.50.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The business had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group’s revenue for the quarter was up 63.7% on a year-over-year basis. During the same period last year, the business posted ($0.12) earnings per share. Analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on TMDX. Piper Sandler lowered their price target on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating for the company in a research report on Wednesday. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. TD Cowen decreased their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday. Robert W. Baird dropped their price objective on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. Finally, Stephens increased their price target on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, TransMedics Group has an average rating of “Buy” and an average price target of $131.80.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.